Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 10:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 864 matching trials from the live ClinicalTrials.gov search.
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Betahistine Hydrochloride, Placebo Capsule
Drug
Lead sponsor
P2D, Inc.
Industry
Eligibility
22 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
SHP465 12.5mg capsules (one capsule daily), Placebo, SHP465 12.5mg, 25mg, or 37.5mg capsules (one capsule daily)
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
45
States / cities
Encino, California • Los Alamitos, California • Newport Beach, California + 40 more
Conditions
ADHD, Anxiety, Generalized Anxiety, Social Anxiety Disorder
Interventions
Centanafadine, Placebo
Drug · Other
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
46
States / cities
Dothan, Alabama • Little Rock, Arkansas • Rogers, Arkansas + 41 more
Completed No phase listed Observational Accepts healthy volunteers Results available

Association Between Smoking, Brain Activity, Genes, and ADHD

NCT00915798
Conditions
Smoking, Withdrawal Nicotine, ADHD
Interventions
Cigarette smoking, Abstinence
Behavioral
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 45 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Santa Ana, California
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Vyvanse (lisdexamphetamine), Behavior Parent Training
Drug · Behavioral
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
21 Years to 50 Years · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
HLD200, Placebo
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
6 Years to 12 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
4
States / cities
Newport Beach, California • Marshfield, Massachusetts • Las Vegas, Nevada + 1 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Trial of Aripiprazole in the Treatment of CD in Adolescents

NCT00250705
Conditions
Conduct Disorder
Interventions
Aripiprazole
Drug
Lead sponsor
University of Iowa
Other
Eligibility
13 Years to 17 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate, placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Years to 11 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Executive Training of Attention and Metacognition (ETAM), Attention Control
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Years to 5 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Tourette Syndrome, Chronic Tic Disorder, Oppositional Defiant Disorder, ADHD
Interventions
Anger control training
Behavioral
Lead sponsor
Yale University
Other
Eligibility
11 Years to 16 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Attention Deficit Hyperactivity Disorder (ADHD), Impulsive Aggression
Interventions
Functional Magnetic Resonance Imaging (fMRI), Magnetic Resonance Spectroscopy (MRS), Point Subtraction Aggression Paradigm (PSAP) Task, SPN-810, Placebo
Diagnostic Test · Behavioral · Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
8 Years to 12 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
3
States / cities
Lakeland, Florida • Maitland, Florida • Tampa, Florida
Conditions
Attention Deficit Disorder With Hyperactivity, Substance-Related Disorders
Interventions
Atomoxetine hydrochloride, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
15 Years to 30 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Autism Spectrum Disorder
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
16 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Cambridge, Massachusetts
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Healthy Sleep Duration, Shortened Sleep Duration
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
14 Years to 17 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Quillivant Oral Suspension XR, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 12 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Irvine, California • Las Vegas, Nevada
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
OPDC-34712, Placebo, Stimulant Therapy
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
35
States / cities
Little Rock, Arkansas • Beverly Hills, California • Irvine, California + 32 more
Conditions
ADHD
Interventions
Centanafadine, Methylphenidate, Lisdexamfetamine
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
ADHD
Interventions
SPD489, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
13 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
6
States / cities
Little Rock, Arkansas • Bradenton, Florida • Overland Park, Kansas + 3 more
Completed No phase listed Observational Results available

The Parenting Young Children Check-up: Proof-of-Concept Trial

NCT04113304
Conditions
Disruptive Behavior Disorders
Interventions
Parenting Young Children Check-up (PYCC)
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 99 Years
Enrollment
6 participants
Timeline
2019 – 2020
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
ADHD
Interventions
SPD503-AM, SPD503-PM, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years to 17 Years
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
61
States / cities
Dothan, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 53 more
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
CLONICEL (Clonidine HCl sustained release)
Drug
Lead sponsor
Shionogi
Industry
Eligibility
6 Years to 17 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
27
States / cities
Little Rock, Arkansas • El Centro, California • Irvine, California + 23 more
Conditions
Developmental, Behavioral and Mental Health, Adhd, Depression, Anxiety, Developmental Delay, Autism, Behavioral Problems
Interventions
Telehealth Intervention
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
6
States / cities
Canoga Park, California • Pacoima, California • San Fernando, California + 3 more
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Mixed salts of a single-entity amphetamine, Atomoxetine hydrochloride
Drug
Lead sponsor
Shire
Industry
Eligibility
19 Years to 25 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
ADHD
Interventions
ADHD Therapy
Device
Lead sponsor
Lumos Labs, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
Jacksonville, Florida • Lakeland, Florida • Rochester Hills, Michigan + 2 more